US FDA restricts use of monoclonal antibodies to treat Omicron cases |
Editorial
eMediNexus Coverage from: 
US FDA restricts use of monoclonal antibodies to treat Omicron cases
Dr Veena Aggarwal, Consultant Womens’ Health, CMD and Editor-in-Chief, IJCP Group & Medtalks Trustee, Dr KK’s Heart Care Foundation of India,  27 January 2022
Coronavirus Live Count Map India

remove_red_eye 1497 Views
COVID-19 Vaccine Updates


#Multispeciality

5 Read Comments                

Given their lack of neutralizing efficacy against the Omicron variant, the US FDA has restricted the use of bamlanivimab with etesevimab and casirivimab with imdevimab. These monoclonal antibody treatments are now authorized to be used “only when the patient is likely to have been infected with or exposed to a variant that is susceptible to these treatments”. The Omicron variant of SARS-CoV-2 has replaced the till now dominant delta variant in the United States and accounts for ...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now